The use of lanreotide to prevent pancreatic fistula after pancreaticoduodenectomy. A preliminary study;Usage du lanreotide dans la prevention des fistules pancreatiques apres duodeno-pancreatectomie cephalique. Etude preliminaire

Chirurgie

Volumn 124, Issue 6, 1999, Pages 661-665

  Slim, K ^a   Buc, E ^a   Lescure, G ^a   Chanudet, M ^a   Pezet, D ^a   Chipponi, J ^a  

^a HÔTEL DIEU   (France)

Author keywords

Pancreatic cancer; Pancreatic fistula; Pancreatoduodenectomy; Prevention

Indexed keywords

AMYLASE; ANGIOPEPTIN; LONG ACTING DRUG; SOMATOSTATIN DERIVATIVE; CYCLOPEPTIDE; DRUG DERIVATIVE; SOMATOSTATIN;

ABDOMINAL DRAINAGE; ADULT; ANASTOMOSIS DEHISCENCE; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; PANCREAS CANCER; PANCREAS FISTULA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; REOPERATION; CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY;

HUMANS; MIDDLE AGED; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 0033254384     PISSN: 00014001     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4001(99)00076-8     Document Type: Article

References (20)

1. Lillemoe K.D. Current management of pancreatic carcinoma. Ann Surg. 221:1995;133-148.
2. Rosewicz S., Wiedenmann B. Pancreatic carcinoma. Lancet. 349:1997;485-489.
3. Bartoli F.G., Arnone G.B., Ravera G., Bach V. Pancreatic fistulas and relative mortality in malignant disease after pancreatoduodenectomy. Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res. 11:1991;1831-1848.
4. Trede M., Schwall G. The complications after pancreatectomy. Ann Surg. 207:1988;39-47.
5. Pellegrini C.A., Heck C.F., Raper S., Way L.W. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg. 124:1989;778-781.
6. Schirmer W.J., Rossi R.L., Braasch J.W. Common difficulties and complications in pancreatic surgery. Surg Clin North Am. 71:1991;1391-1417.
7. Raptis S., Schlegel W., Lehmann E., Dollinger H.C., Zoupas C. Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism. 27:1978;1321-1328.
8. Köhler E., Beglinger C., Dettwiler S., Whitehouse I., Gyr K. Effect of a new somatostatin analog sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Pancreas. 2:1986;154-159.
9. Büchler M., Friess H., Klempa I., Hermanek P., Sulkowski U., Becker H. Role of octreotide in the prevention of post-operative complications following pancreatic resection. Am J Surg. 163:1992;125-130.
10. Pederzoli P., Bassi C., Falconi M., Camboni M. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Br J Surg. 81:1994;265-269.
11. Friess H., Beger H.G., Sulkowski U., Becker H., Hofbauer B., Dennler H.J. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 82:1995;1270-1273.
12. Montorsi M., Zago M., Mosca F., Capussotti L., Zotti E., Ribotta G. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: A prospective, controlled, randomized clinical trial. Surgery. 117:1995;26-31.
13. Lowy A.M., Lee J.E., Pisters P.W.T., Davidson B.S., Fenoglio C.J., Stanford P. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 226:1997;632-641.
14. Briceno Delgado F.J., Lopez, Cillero P., Rufian Pena S., Solozano, Peck G., Fugarolas G., Pera Madrazo C. Prospective and randomized study on the usefulness of octreotide in the prevention of complications after cephalic duodenopancreatectomy. Rev Esp Enferm Dig. 90:1998;687-694.
15. Fourtanier G., Chipponi J., Fagniez P.L., Hay J.M., Haddad A.E., Fingerhut A. Octreotide in the prevention of surgical complications after pancreatectomy. A prospective randomized multicenter study. Hepatogastroenterology. 45 (suppl):1998;A429.
16. Gouillat C., Chipponi J., Partensky C., Baulieux J., Saric J., Gayet B. Effet de la somatostatine sur le moignon pancréatique après duodénopancréatectomie céphalique (DPC). Chirurgie. 123:1998;525.
17. Sassolas G., Khalfallah Y., Chayvialle J.A., Cohen R., Merabet S., Casez J.P. Effect of the somatostatine analogue BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 68:1989;239-246.
18. Al Sharaf C., Ishe I., Dawiskiba S., Andrensandberg A. Characteristics of the gland remnant predict complications after subtotal pancreatectomy. Dig Surg. 14:1997;101-106.
19. Barberat P.O., Friess H., Uhl W., Büchler M.W. The role of octreotide in the prevention of complications following pancreatic resection. Digestion. 60 (suppl 2):1999;15-22.
20. Kuhn J.M., Legrand A., Ruiz J.M., Obach R., De Ronzan J., Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide in normal healthy volunteers. Br J Clin Pharmacol. 38:1994;213-219.